PMID- 38292853
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20240201
IS  - 1177-5467 (Print)
IS  - 1177-5483 (Electronic)
IS  - 1177-5467 (Linking)
VI  - 18
DP  - 2024
TI  - Comparative Analysis of the Osmoprotective Effects of Daily Disposable Contact 
      Lens Packaging Solutions on Human Corneal Epithelial Cells.
PG  - 247-258
LID - 10.2147/OPTH.S437841 [doi]
AB  - PURPOSE: Contact lens (CL) wear challenges the balance of the ocular surface 
      environment by increasing water evaporation and tear osmolarity. Maintaining 
      ocular surface homeostasis during CL wear remains a goal of lens manufacturers 
      and an important consideration for eye care professionals. The purpose of this 
      study was to measure the metabolic activity and inflammatory responses of a 
      transformed human corneal epithelial cell (THCEpiC) line under hyperosmotic 
      conditions in the presence of CL packaging solutions. METHODS: CL packaging 
      solutions sampled from seven daily disposable silicone hydrogel CL blister 
      packages were prepared at 25% and made hyperosmolar (400 mOsm/kg) with NaCl. 
      THCEpiCs were incubated with each solution for 24 hr, after which cell culture 
      supernatants were collected. THCEpiC metabolic activity was determined by an 
      alamarBlue assay. Concentrations in cell culture supernatants of inflammatory 
      cytokine (interleukin [IL]-6) and chemokine (IL-8), as well as monocyte 
      chemoattractant protein-1 (MCP-1), were quantitated by specific enzyme-linked 
      immunosorbent assays. RESULTS: THCEpiC metabolic activity under hyperosmolar 
      conditions decreased in the presence of somofilcon A and senofilcon A solutions 
      (p=0.04 and 0.004, respectively), but no other solution (all p>/=0.09). 
      Concentrations of IL-6 increased in the presence of delefilcon A, somofilcon A, 
      narafilcon A, and senofilcon A solutions (all p</=0.001), but no other solution 
      (all p>/=0.08), while those of IL-8 increased in the presence of all solutions (all 
      p</=0.03) but kalifilcon A (p>0.99), and those of MCP-1 increased in the presence 
      of delefilcon A, verofilcon A, somofilcon A, and stenfilcon A solutions (all 
      p<0.0001), but no other solution (all p>0.99). CONCLUSION: CL packaging solutions 
      differ in their capacity to inhibit epithelial inflammation. THCEpiC inflammatory 
      response was less in the presence of a CL packaging solution containing 
      osmoprotectants than in solutions lacking osmoprotectants under moderately 
      hyperosmolar conditions in vitro. Clinical studies are warranted to further 
      substantiate the benefit of osmoprotectants.
CI  - (c) 2024 VanDerMeid et al.
FAU - VanDerMeid, Karl R
AU  - VanDerMeid KR
AD  - Vision Care, Bausch & Lomb Incorporated, Rochester, NY, USA.
FAU - Byrnes, Mirzi Grace
AU  - Byrnes MG
AD  - Vision Care, Bausch & Lomb Incorporated, Rochester, NY, USA.
FAU - Millard, Kimberly
AU  - Millard K
AD  - Vision Care, Bausch & Lomb Incorporated, Rochester, NY, USA.
FAU - Scheuer, Catherine A
AU  - Scheuer CA
AD  - Vision Care, Bausch & Lomb Incorporated, Rochester, NY, USA.
FAU - Phatak, Nitasha R
AU  - Phatak NR
AUID- ORCID: 0000-0002-2107-985X
AD  - Vision Care, Bausch & Lomb Incorporated, Rochester, NY, USA.
FAU - Reindel, William
AU  - Reindel W
AD  - Vision Care, Bausch & Lomb Incorporated, Rochester, NY, USA.
LA  - eng
PT  - Journal Article
DEP - 20240125
PL  - New Zealand
TA  - Clin Ophthalmol
JT  - Clinical ophthalmology (Auckland, N.Z.)
JID - 101321512
PMC - PMC10825585
OTO - NOTNLM
OT  - TFOS
OT  - contact lens
OT  - cornea
OT  - homeostasis
OT  - hyperosmolarity
OT  - osmoprotection
COIS- All authors are employees of Bausch & Lomb Incorporated. Ms Catherine Scheuer 
      reports a patent US 17/398,556 pending to Bausch+Lomb, a patent Taiwan 110129328 
      pending to Bausch+Lomb, a patent PTC/EP2021/072140 pending to Bausch+Lomb. Dr 
      William Reindel has a patent WO2022034010A1 pending to Bausch+Lomb. The authors 
      report no other conflicts of interest in this work.
EDAT- 2024/01/31 06:43
MHDA- 2024/01/31 06:44
PMCR- 2024/01/25
CRDT- 2024/01/31 04:16
PHST- 2023/09/22 00:00 [received]
PHST- 2023/12/12 00:00 [accepted]
PHST- 2024/01/31 06:44 [medline]
PHST- 2024/01/31 06:43 [pubmed]
PHST- 2024/01/31 04:16 [entrez]
PHST- 2024/01/25 00:00 [pmc-release]
AID - 437841 [pii]
AID - 10.2147/OPTH.S437841 [doi]
PST - epublish
SO  - Clin Ophthalmol. 2024 Jan 25;18:247-258. doi: 10.2147/OPTH.S437841. eCollection 
      2024.